Eli Lilly and Co. has reported promising results from its Phase 3 clinical trial of orforglipron, an oral GLP-1 medication designed to aid in diabetes management and weight loss, showing significant reductions in blood sugar levels and weight in individuals with Type 2 diabetes. The trial demonstrated that orforglipron effectively reduced A1C levels, aligning with the performance of existing injectable GLP-1 drugs, and represents a significant innovation by offering a more accessible oral alternative. If approved, orforglipron would become the second oral GLP-1 medication in the U.S., potentially expanding treatment options and providing a convenient alternative to injections for diabetes patients.
Posts tagged as “Eli Lilly”
Sanofi, one of the three major insulin makers in the US, has announced a 78% reduction in the list price of its most widely prescribed insulin, Lantus, and a $35 monthly cap for those with private insurance. Uninsured Americans are eligible for Sanofi’s Insulins Valyou Savings Program. President Joe Biden praised the move, and Eli Lilly and Novo Nordisk have also announced changes to how they price their insulin this month. The Inflation Reduction Act and the actions of the three major insulin makers are a step in the right direction to make insulin more accessible and affordable for people with diabetes.
Novo Nordisk, a Danish pharmaceutical firm, has announced that it will reduce the U.S. list price of some of its insulin products by up to 75%, effective January 1, 2024. This follows a similar move by Eli Lilly earlier this month, and is part of a larger effort to make insulin more affordable for people with diabetes. The price cuts are expected to provide relief to those who rely on insulin to manage their condition.
Eli Lilly & Co. announced Wednesday that it will reduce prices for some of its older insulins and expand a cap on costs insured patients pay when they fill prescriptions, providing critical relief to people with diabetes who can face annual costs of more than $1,000 for insulin. The drugmaker said the cap on out-of-pocket costs will take effect immediately, though the high cost of insulin in the U.S. is still a major issue.
Eli Lilly has announced a 70% price cut for its most commonly used forms of insulin, with a list price of $25 a vial as of May 1, and out-of-pocket costs capped at $35 a month for those with commercial insurance. The move comes in response to criticism of insulin prices, which have led to rationing and other health risks for those with diabetes. Eli Lilly is also expanding its Insulin Value Program to help make insulin more accessible and affordable.